<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00129363</url>
  </required_header>
  <id_info>
    <org_study_id>SB 105517-396</org_study_id>
    <nct_id>NCT00129363</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety of Twice Daily Oral Carvedilol</brief_title>
  <official_title>A Multicenter, Open Label Extension Study to Evaluate the Safety of Twice Daily Oral Carvedilol in Pediatric Patients With Chronic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaddy, Robert, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shaddy, Robert, M.D.</source>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the long-term safety of carvedilol in pediatric
      patients with chronic heart failure, who completed the Pediatric Carvedilol Study 321.
      Carvedilol will be provided as open-label therapy for a period of at least 6 months (or until
      termination of the study) by SmithKline Beecham Corporation d/b/a GlaxoSmithKline (GSK) or
      the University Sponsor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label, uncontrolled, extension study is designed to assess the long-term safety of
      carvedilol in pediatric patients with heart failure and includes the following phases:

        1. Screening Phase (coincides with the final maintenance Month 6 Visit in the 321 study

        2. Down-/Up-titration Phase

        3. Maintenance Phase

        4. Down-titration

        5. Follow-up
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dose tolerability</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>growth and development</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>physical exam (PE) including cardiopulmonary examination</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>blood pressure (BP), heart rate (HR), height (Ht) and weight [Wt] (including %)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>laboratory safety assessments</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>pregnancy test, if applicable</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>an echocardiographic measurement</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>reporting of all adverse events [AEs] (serious and non-serious)</measure>
  </primary_outcome>
  <enrollment type="Actual">75</enrollment>
  <condition>Congestive Heart Failure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients with chronic symptomatic congestive heart failure (CHF) due to
             systemic ventricular systolic dysfunction, who are receiving standard heart failure
             therapy and have successfully completed the maintenance phase of the Pediatric
             Carvedilol Study 321.

          -  Parent or guardian of patient able and willing to give written informed consent. The
             written assent from children &gt; 9 years of age is also required.

        Exclusion Criteria:

          -  A patient who, in the opinion of the investigator, would not benefit from open-label
             carvedilol.

          -  A patient who, in the opinion of the investigator, is incapable of cooperating with
             the requirements of this study.

          -  A patient treated with the following medications at the time of entry in the study:

               -  Monoamine oxidase (MAO) inhibitors;

               -  Calcium entry blockers;

               -  Î±- blockers, or labetalol;

               -  Disopyramide, flecainide, encainide, moricizine, propafenone;

               -  Intravenous inotropes such as dobutamine or intravenous vasodilator agents such
                  as amrinone or milrinone;

               -  Intravenous CHF medications (e.g. diuretics, digoxin);

               -  Beta-blockers, other than double-blind carvedilol.

          -  Uncorrected primary obstructive or severe regurgitative valvular disease, nondilated
             (restrictive) or hypertrophic cardiomyopathy, or significant systemic ventricular
             outflow obstruction.

          -  A patient with any of the following contra-indications to beta-blocker therapy:

               -  Heart rate &lt; 2nd percentile for age;

               -  Unacceptable blood pressure. Sitting (supine in infants) systolic blood pressure
                  must be &gt; 85 mm Hg in teens; &gt;75 mm Hg in school-aged children; and &gt;65 mm Hg in
                  infants;

               -  Sick sinus syndrome, second or third degree atrioventricular (AV) block, unless
                  treated with a permanent pacemaker;

               -  History or current clinical evidence of moderate-to-severe obstructive pulmonary
                  disease or reactive airway diseases (e.g., asthma) requiring therapy;

               -  Unstable insulin-dependent diabetes mellitus.

          -  Renovascular hypertension or evidence of pulmonary hypertension (pulmonary vascular
             resistance index &gt; 6 Wood units m2) unresponsive to vasodilator agents such as oxygen,
             nitroprusside, or nitric oxide

          -  A patient with any one of these general exclusion criteria:

               -  Significant renal (serum creatinine &gt; 2.0), hepatic (serum AST and/or ALT &gt; 3
                  times upper limit of normal), gastrointestinal, or biliary disorders that could
                  impair absorption, metabolism, or excretion of orally administered medications;

               -  Endocrine disorders such as pheochromocytoma, active hyperthyroidism and
                  untreated hypothyroidism;

               -  Any illness other than heart failure that may limit survival within 1 year (e.g.
                  neoplasm);

               -  Girls of childbearing potential who are pregnant or sexually active and not
                  taking adequate contraceptive precautions (e.g., intrauterine device [IUD] or
                  oral contraceptives).

          -  A patient who received any investigational drug within the preceding 30 days except
             blinded medication in Pediatric Carvedilol Study 321. An investigational drug is
             defined as any agent (placebo or drug) dispensed as part of a research study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Robert E Shaddy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mattel Children's Hospital at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S. Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-2196</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110-1014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-1537</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Children's Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37332</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-7794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Childrens Hospital and Regional Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2005</study_first_submitted>
  <study_first_submitted_qc>August 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2005</study_first_posted>
  <last_update_submitted>December 24, 2008</last_update_submitted>
  <last_update_submitted_qc>December 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Robert E Shaddy, MD</name_title>
    <organization>The Children's Hospital of Philadelphia</organization>
  </responsible_party>
  <keyword>Adolescent</keyword>
  <keyword>Adrenergic alpha-Antagonists/therapeutic use</keyword>
  <keyword>Adrenergic alpha-Antagonists/pharmacokinetics</keyword>
  <keyword>Adrenergic alpha-Antagonists/administration &amp; dosage</keyword>
  <keyword>Adrenergic beta-Antagonists/therapeutic use</keyword>
  <keyword>Adrenergic beta-Antagonists/pharmacokinetics</keyword>
  <keyword>Adrenergic beta-Antagonists/administration &amp; dosage</keyword>
  <keyword>Age Factors</keyword>
  <keyword>Carbazoles/therapeutic use</keyword>
  <keyword>Carbazoles/administration &amp; dosage</keyword>
  <keyword>Child</keyword>
  <keyword>Child, Preschool</keyword>
  <keyword>Drug Administration Schedule</keyword>
  <keyword>Female</keyword>
  <keyword>Heart Failure, Congestive/etiology</keyword>
  <keyword>Heart Failure, Congestive/drug therapy</keyword>
  <keyword>Heart Failure, Congestive/blood</keyword>
  <keyword>Human</keyword>
  <keyword>Infant</keyword>
  <keyword>Infant, Newborn</keyword>
  <keyword>Male</keyword>
  <keyword>Natriuretic Peptide, Brain/blood</keyword>
  <keyword>Placebos</keyword>
  <keyword>Propanolamines/therapeutic use</keyword>
  <keyword>Propanolamines/administration &amp; dosage</keyword>
  <keyword>Prospective Studies</keyword>
  <keyword>Support, Non-U.S. Gov't</keyword>
  <keyword>Treatment Outcome</keyword>
  <keyword>Ventricular Dysfunction/drug therapy</keyword>
  <keyword>Ventricular Dysfunction/complications</keyword>
  <keyword>Ventricular Dysfunction/blood</keyword>
  <keyword>Ventricular Function/drug effects</keyword>
  <keyword>Ventricular Remodeling/drug effects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Adrenergic alpha-Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

